MedTrace Logo

Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer

NCT02524951 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2018-05-18

No results posted yet for this study

Summary

This is a Phase I, open-label, dose escalation study. MSI-1436 will be administered as a single intravenous infusion twice a week for 3 weeks on a 4-week cycle.

Conditions

Interventions

DRUG

MSI-1436C

Dose escalation, single intravenous infusion twice a week for 3 weeks on a 4-week cycle.

Sponsors & Collaborators

  • DepYmed Inc.

    collaborator INDUSTRY

  • Northwell Health

    lead OTHER

Principal Investigators

  • Daniel Budman, MD · North Shore LIJ Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-07-31
Completion
2018-05-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02524951 on ClinicalTrials.gov